Implementation of First-trimester Screening and preventiOn of pREeClAmpSia Trial (FORECAST)

NACompletedINTERVENTIONAL
Enrollment

42,454

Participants

Timeline

Start Date

July 31, 2019

Primary Completion Date

June 15, 2023

Study Completion Date

August 15, 2023

Conditions
Pre-Eclampsia
Interventions
OTHER

Low-dose aspirin in women with high risk of preeclampsia

Low-dose aspirin 150-162 mg/night or 100 mg/night if body weight \<40 Kg, from \<15 weeks till 36 weeks or, in the event of early delivery, at the onset of labor

Trial Locations (19)

Unknown

Guangzhou Women and Children's Medical Center, Guangzhou

Kunming Angel Women & Children Hospital, Kunming

Nanjing Drum Tower Hospital, Nanjing

Kwong Wah Hospital, Hong Kong

Harapan Kita Hospital, Jakarta

Clinical Research Institute of Fetal Medicine, Osaka

Showa University Hospital, Tokyo

Japan Society for the Study of Hypertension in Pregnancy, Toyama

Pusat Perubatan Universiti Kebangsaan Malaysia (UKM) Medical Centre, Bandar Tun Razak

Philippine General Hospital, Manila

National University Hospital, Singapore

Chang Gung Hospital, Taipei

Taiji Clinic, Taipei

Chulalongkorn University Hospital, Bangkok

Siriraj Hospital, Bangkok

Maharaj Nakorn Chiang Mai Hospital, Chiang Mai

Thammasat University Hospital, Khlong Luang

Hanoi Obstetrics & Gynecology Hospital, Hanoi

Shatin

Prince of Wales Hospital, Hong Kong

All Listed Sponsors
lead

Chiu Yee Liona Poon

OTHER

NCT03941886 - Implementation of First-trimester Screening and preventiOn of pREeClAmpSia Trial (FORECAST) | Biotech Hunter | Biotech Hunter